BioSolar’s partner to manufacture & test commercial-grade Li-ion cells
By Nikita Chaurasia  Date: 2019-03-06

BioSolar’s partner to manufacture & test commercial-grade Li-ion cells
  • The company has successfully completed the initial phase of material preparation for developing full cell Li-ion prototype batteries.
  • The company’s technology partner would now be handling the building & testing portion of the program.

BioSolar, Inc., a Silicon Valley based energy storage technology and materials developer, has reportedly announced that it has completed the initial phase of material preparation for developing full cell Li-ion prototype batteries.

Supposedly, the company would now be collaborating with its South Korea based cell manufacturing partner to transition into the development and testing portion of the battery development program.

According to a press release by BioSolar Inc., the company’s Korean cell manufacturing partner has already commenced with the preparation procedures to produce the first batch of BioSolar commercial-grade Li-ion cylindrical cell prototype 21700. The first prototype batch would be tested to verify their key performance metrics in terms of cell energy capacity.

Following the successful production as well as testing of the first prototype batch, the company’s partner would be manufacturing additional prototype batches to verify other of the battery’s key performance metrics.

BioSolar believes that the innovative Lithium-ion cell design is capable of demonstrating commercial viability and attain increased exposure to the company’s customers, who could test the product and ultimately incorporate the additive technology into their businesses.

The CEO of BioSolar, Dr. David Lee stated that the company’s aim is to demonstrate the product’s technological feasibility along with its cost benefits to the customer. The company believes that the technology would enable higher energy and power capabilities, he said.

The firm’s eventual goal is to showcase that its additive technology could enhance and surpass performance objectives for its customers without having to disrupt their infrastructure and manufacturing processes while reducing costs, Dr. Lee added.

Reports suggest that the company has yet to unveil the financial information related to its Li-ion cell program collaboration with its Korean cell manufacturing partner.

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Fragomen acquires SimpleCitizen to reinforce its immigration services
Fragomen acquires SimpleCitizen to reinforce its immigration services
By Nikita Chaurasia

In a recent turn of events, Fragomen, Del Rey, Bernsen & Loewy, LLP, a leading corporate immigration law company has reportedly joined hands with SimpleCitizen Inc. to form Fragomen Technologies Inc., a new subsidiary which will provide a combina...

Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
By Nikita Chaurasia

Solar project development and asset management major, Nautilus Solar Energy LLC, has reportedly announced its acquisition of two solar portfolios in Rhode Island and Oregon amounting to a total of nearly 17 MW from leading solar energy developer, Pin...

Locate Bio obtains multiple late stage orthobiologics assets from RCSI
Locate Bio obtains multiple late stage orthobiologics assets from RCSI
By Nikita Chaurasia

Regenerative medicine major, Locate Bio, has reportedly announced its in-licensing of several late stage orthobiologics assets from the RCSI University of Medicine and Health Sciences. Sources state that the technologies created by the RCSI Tissue E...

Roche acquires Inflazome to gain control over inflammatory treatments
Roche acquires Inflazome to gain control over inflammatory treatments
By Nikita Chaurasia

In a recent turn of events, Swiss healthcare giant, F. Hoffmann-La Roche AG has reportedly acquired an Irish biotech firm Inflazome Ltd. for approximately USD 451 million (€380 million). As per the agreement, Roche will acquire complete rights ...

Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
By Nikita Chaurasia

Innovent Biologics Inc., in collaboration with American pharmaceutical giant Eli Lilly and Company, have reportedly announced that the biomarker results of ORIENT-11 trials which were displayed during a mini verbal presentation at ESMO (European Soci...